| abstract |
Compounds represented by the general formula (I), salts of the same, solvates of both, or prodrugs thereof: (I) (wherein each symbol is as defined in the description). Since the compounds of the invention bind to LPA receptors (particularly EDG-2) and thus antagonize them, they are useful in the prevention and/or treatment of urologic diseases (such as symptoms due to prostatic hypertrophy or neurogenic bladder; tumor of spinal cord; intervertebral disk hernia; spinal canal stenosis; symptoms caused by diabetes; obstruction of lower urinary tract; inflammatory diseases of lower urinary tract; and polyuria), cancer-related diseases, proliferative diseases, inflammatory diseases, immunopathies, diseases due to secretion disturbance, brain-related diseases and/or chronic diseases. |